Glioblastoma (GBM) is a fatal type of brain cancer or primary glial neoplasm, mostly targeting aged populations. The average survival is only 15 mouths from the date of occurrence. It is often observed, the invasive nature of tumour is the main reason for poor prognosis and strong recurrence of GBM in patients even after prescribed treatments. Despite all type of therapy, it is necessary to understand the various molecular mechanisms and signalling pathways to identify targets for GBM treatment. This compilation is specifically design to discuss about Wnt signalling and Hedgehog-GLI1 pathways which have positive and negative regulation against GBM. The recent research finding associated with different signalling pathways for GBM was also been discussed within this article.

European Journal of Clinical Oncology Cancer poses a major challenge to development; it undermines socio-economic advances throughout the world. It is estimated that the number of patients with cancer would increase from 12.7 million in the year 2008 to 22.2 million by 2030. It is universally agreed that the condition is reaching epidemic proportions. At this time, the European Journal of Clinical Oncology is conveniently placed in the scholarly communication milieu to help counter the menace of cancer by aiding the development of novel treatment strategies, by providing novel insights into the mechanisms underlying this complex disease.

European Journal of Clinical Oncology publishes peer-reviewed original research articles, review articles, short communications, expert opinions, commentaries and letters/editorials based on open access policy. Author(s) are invited to submit their manuscripts as an e-mail attachment for fast and efficient processing. Aims & scope of the journal, key words, indexing as well as bibliographic information can be accessed at https://www.iomcworld.org/european-clinical-oncology.html

John Robert

Managing Editor
European Journal of Clinical Oncology
Mail ID: oncology@scholarlymed.com
WhatsApp no: + 1-504-608-2390